Lucid Diligence Brief - BioPharma

Curium Lantheus Merger | Lucid Diligence Brief

Curium’s proposed acquisition of Lantheus reshapes the radiopharmaceutical…


Lucid Diligence Brief - BioPharma

Roche Ivy Tech Laboratory Workforce Partnership | Lucid Diligence Brief

Roche Diagnostics and Ivy Tech launch an Indiana laboratory workforce…


Lucid Diligence Brief - Tech

Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief

Nucleai broadened its University of Glasgow collaboration to expand academic…


Lucid Diligence Brief - BioPharma

Merck KGaA Bio-Techne Deal | Lucid Diligence Brief

Merck KGaA’s US$11.3bn Bio-Techne acquisition tests workflow depth, integration…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology

Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Helio Genomics and Syneos Health Deal

Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition

Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership

Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Roche to acquire PathAI

Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration

Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million

Lucid Diligence Brief: Agilent acquires Biocare Medical for $950 million…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…


Privacy Preference Center